Abstract:Ethnopharmacological relevance Transcatheter arterial chemoembolization (TACE) is recommended as the first-line therapy for unresected primary liver cancer (PLC), but only partial patients could benefit from TACE due to the serious adverse reactions. Clearing heat and resolving toxin (CHRT), one of most critical traditional Chinese medicine (TCM) therapeutic principles, has been widely used in the treatment of PLC patients especially after TACE. However, there is no enough clinical evidence to confirm the efficacy and safety of the combined therapy. Aim of the study To comprehensively evaluate the efficacy and safety of the combined CHRT-CHF with TACE in the treatment of PLC. Materials and methods 7 databases were searched from their inception until February 1, 2023. The primary outcomes included survival rate (1-, 2-year), objective response rate (ORR) and disease control rate (DCR), liver function indicators (AST, ALT), adverse reactions including fever, upper digestive tract side and myelosuppression, AFP were selected as the secondary outcomes. RevMan5.4 software was used to evaluate the quality of included studies; meta-analysis, subgroup analysis, meta-regression analysis, publication bias and trial sequential analyses (TSA) was conducted by Stata software 12.0. Results There were 40 RCTs involving 3649 patients. Patients treated with TACE plus CHRT-CHF showed significantly better 1-, 2-year survival (respectively: OR, 2.23 [1.67–2.97]; OR, 2.13 [1.56–2.92]), ORR (OR, 2.14 [1.82–2.52]), DCR (OR, 2.13 [1.73–2.62]) compared with TACE alone. There was a decreased incidence of aspartate transaminase (AST), alanine transaminase (ALT), alpha-fetoprotein (AFP) and postembolization syndrome (PES) in patients receiving the combined TACE with CHRT-CHF compared with TACE alone. Subgroup analysis found that lower proportion (20–30%) of CHRT-CHF significantly enhanced survival rate and DCR, higher proportion (≥40%) of CHRT-CHF reduced PES after TACE treatment. Conclusion The efficacy and safety of the combined CHRT-CHF with TACE were validated in this meta-analysis, the optimal proportion of CHRT-CHF in enhancing the efficacy may be 20–30%; Additionally, higher proportion (≥40%) of CHRT-CHF appears to reduce PES after TACE treatment. The potential role of combined relative proportion of CHRT-CHF with TACE should be emphasized in clinic.

Comparative Study on Clinical Efficacy of Comprehensive Treatment Plan of TCM and TACE in Treatment of Barcelona Stage C Liver Cancer

Combined Three Intervened Treatment of TACE,PEI And PVC in Advanced Liver Cancer

[Clinical Evaluation of Integration of Transcatheter Arterial Chemoembolization and Traditional Chinese Medicine in Treating Metastatic Liver Cancer].

Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization.

Traditional Chinese Medicine Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma

Survival Analysis of TACE Monotherapy Vs. Combination Therapy in BCLC B and C Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

A Comparison of Survival in Hepatocellular Carcinoma Patients with BLCC Stage B and C Between Hepatic Resection and Transarterial Chemoembolization

Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma.

The therapeutic principle of combined clearing heat and resolving toxin plus TACE on primary liver cancer: A systematic review and meta-analysis

A Multiregional,multicenter,randomized and Controlled Study on the Treatment of Chronic Liver Failure by Combined Traditional Chinese and Western Medicine

Impact of Treatment-Duration-ratio of Traditional Chinese Medicine on Survival Period of Primary Liver Cancer -A Real-World Study

Comparison of Chemoembolization with CalliSpheres® Microspheres and Conventional Chemoembolization in the Treatment of Hepatocellular Carcinoma: a Multicenter Retrospective Study.

Effect of Yiqi Jiedu traditional Chinese medicine plus transcatheter arterial chemoembolization on primary hepatocellular carcinoma and its influence on T lymphocyte subsets,GP - 73 and GPC - 3 levels

Clinical Observation of the Union Treatment of Hepatic Transcatheter Arterial Chemoembolization and Percutaneous Microwave Coagulation Therapy for Hepatic Cellular Carcinoma

Clinieal studies on the therapeutic effeets of combined therapy with TACE and Qi-boosting toxin-resolving granule on hepatic carcinoma

Clinical value of liver cancer staging in predicting the survival time in Chinese patients after receiving TACE: comparison of Hong Kong liver cancer staging system with Barcelona clinic liver cancer staging system

Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study

Effect of TACE Combined with Stereotactic Body X-knife on the Patients with Hepatocellular Carcinoma

[A Retrospective Study of Chinese Herbal Medicine Combined with Systemic Chemotherapy And/or Regional Arterial Perfusion for Pancreatic Cancer with Liver Metastases].

TACE Combined with Thermotherapy for Primary Hepatic Carcinoma; A Meta-Analvsis

The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study.